Guardian Pharmacy Services Inc (GRDN) Stock Analysis
Verdict: WATCH (do not buy)
Strong balance sheet and LTC market tailwinds offset high 37.5x P/E valuation and IRA drug price compression risks.
Investment score: 54/100
Analysis as of
Is Guardian Pharmacy Services Inc stock worth reviewing? The TradeMates thesis
Guardian Pharmacy Services delivers resilient operational cash flow ($100.3M operating cash flow in 2025) and benefits from long-term secular growth in assisted living residents served (207,000 in Q1 2026). However, at 37.5x earnings, the valuation leaves minimal margin for error heading into Q3 earnings.
7-factor investment score
- Valuation: 38/100 (weight 20%)
- Financial Health: 78/100 (weight 15%)
- Technical Momentum: 48/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 52/100 (weight 15%)
Guardian Pharmacy Services Inc opportunities and risks
What speaks for GRDN
- Demographic expansion in resident count
What speaks against GRDN
- Regulatory drug price resets and IRA headwind
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GRDN | 37.7x | 1.7x | 20.5x | 21.6% | 4.5% | 3.2% |
| OPCH | 23.5x | 0.8x | 13.9x | 18.2% | 3.7% | 7.4% |
| CRVL | 37.3x | 4.3x | 21.8x | 23.9% | 11.7% | 2.7% |
| PRVA | 101.8x | 1.2x | n/a | 7.6% | 1.2% | -1.7% |
| AVAH | 10.0x | 1.1x | 14.0x | 32.0% | 10.6% | 5.7% |
| MD | 14.0x | 1.2x | 10.2x | 25.9% | 9.0% | 9.5% |
| Peer median | 23.5x | 1.2x | 13.9x | 23.9% | 9.0% | 5.7% |
Frequently asked questions about Guardian Pharmacy Services Inc (GRDN)
Is GRDN stock a good investment?
The TradeMates model rates Guardian Pharmacy Services Inc as WATCH (do not buy) with an investment score of 54/100. Guardian Pharmacy Services delivers resilient operational cash flow ($100.3M operating cash flow in 2025) and benefits from long-term secular growth in assisted living residents served (207,000 in Q1 2026). However, at 37.5x earnings, the valuation leaves minimal margin for error heading into Q3 earnings. This is algorithmic model output, not personal investment advice.
Is GRDN stock a buy?
The TradeMates model verdict for GRDN is WATCH (do not buy) with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.